We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Is The FDA Keeping Us Fat?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Is The FDA Keeping Us Fat?
Business

Is The FDA Keeping Us Fat?

JohnCGoodman
JohnCGoodman
Share
3 Min Read
SHARE

Two-thirds of Americans are overweight or obese. A Gallup poll found that 86% of full-time workers are overweight. A report in Health Affairs by Kenneth Thorpe, shows that 7% weight loss in just a small segment of the older adult population (60-64 year olds) could save Medicare as much as $15 billion.

Two-thirds of Americans are overweight or obese. A Gallup poll found that 86% of full-time workers are overweight. A report in Health Affairs by Kenneth Thorpe, shows that 7% weight loss in just a small segment of the older adult population (60-64 year olds) could save Medicare as much as $15 billion. And the savings could be up to $35 billion if those individuals lost 10% of their body weight.

Despite this, last year the FDA rejected three new obesity therapies — Qnexa, Contrave, and Lorqess — the most promising of which, Qnexa, has been shown to bring about sustained weight loss greater than 10% of a person’s body weight. The FDA wanted additional evidence of the drugs were safe and effective in the short term; and evidence showing long-term weight loss. The rub is that the ingredients in two of the three therapies are known to be safe — they’re already FDA approved and widely available for treating migraines, depression, and other conditions. The first of the three drug makers is now going back to try again, having resubmitted its application for FDA approval.

Arguably, the main reason the FDA is hesitant to approve an obesity drug is because it considers nothing as safe for controlling weight as diet and exercise. However, diet and exercise generally fail. And there are few medications available — most of which are ineffective. That leaves surgery, a drastic step for many with a relatively high risk of death.

More Read

ACOs
Have ACOs Failed to Incentivize Providers?
Pick a Horse and Other Sage Advice About Leadership Decisions
4 Steps for Revitalizing Your Medical Practice’s Brand
Six Secrets to Ramp up Your Revenue Cycle
Physician Marketing Battles You’ll Never Win (and What to Do Instead)

Without prescription weight-loss drugs, people turn to over-the-counter remedies, many of which are not very safe either. These include highly-caffeinated energy drinks that can raise blood pressure and herbal remedies bought on the Internet, many of which come from China and actually contain active ingredients that have been banned by the FDA.

   

TAGGED:FDAobesitypharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Biofeedback Technology in Addiction Treatment: What the Evidence Shows So Far -- AI-generated illustration
Biofeedback Technology in Addiction Treatment: What the Evidence Shows So Far
Addiction Addiction Recovery
September 28, 2026
Charity Care Is Written Into Hospital Policy. It Rarely Makes It Onto the Bill. -- AI-generated illustration
Charity Care Is Written Into Hospital Policy. It Rarely Makes It Onto the Bill.
Business Hospital Administration
September 25, 2026
A Global Perspective on Medicine: Lessons Learned Across Borders -- AI-generated illustration
A Global Perspective on Medicine: Lessons Learned Across Borders
Medicines
September 23, 2026
KMG Psychiatry Discusses the Role of Self-Awareness in Mental Health  -- AI-generated illustration
KMG Psychiatry Discusses the Role of Self-Awareness in Mental Health 
Mental Health
September 23, 2026

You Might also Like

emergency room
BusinessGlobal HealthcareHospital AdministrationNewsPublic Health

Collaborative Learning: Ebola

October 7, 2014
Image
Public HealthWellness

UnitedHealth Group’s JOIN for ME Engages the Entire Family through Workplace Wellness

June 14, 2012

Can a Mandated Health Benefit Violate a Corporation’s Religious Freedom?

January 22, 2014
hospital executives
BusinessHospital AdministrationTechnology

How Hospital Execs Can Keep Up in the Fast-Paced Tech World

February 20, 2015
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?